Prof. Weiwei Wang 王巍炜
Chief Physician, Professor
Department of Thoracic Surgery II, Yunnan Cancer Hospital, Kunming
Public profile Compiled from public listings and PubMed. We do not work directly with this doctor, but we can find a specialist in this field to review your case.
Get a specialist opinionClinical focus: Early diagnosis and management of lung cancer, pulmonary nodules, and ground-glass opacities. Treatment of pleural effusion, esophageal cancer, and mediastinal tumors. Thoracoscopic minimally invasive surgery, including lobectomy, segmentectomy, and extended thymectomy.
Dr. Wang holds a medical doctorate and is a professor and doctoral supervisor at Kunming Medical University. A visiting scholar at Johns Hopkins University, Dr. Wang receives a special allowance from the Yunnan Provincial Government. Recognized as a leading talent in Yunnan healthcare and a key academic backbone at Kunming Medical University.
Professional roles
- Youth Committee Member, Lung Cancer Professional Committee, Chinese Research Hospital Association
- Youth Committee Member, China Tumor Marker Committee
- Secretary, Lung Cancer Professional Committee, Yunnan Preventive Medicine Association
- Committee Member, Chest Tumor Minimally Invasive Therapy Professional Committee, Yunnan Anti-Cancer Association
Name order: in Chinese the family name comes first (Wang Weiwei). Papers usually list the name as Weiwei Wang or Wang W.
Selected publications
17 papers on PubMed matched by name and affiliation; 10 as first or senior author since 2016. Most recent first- or senior-author papers:
- Cell Signal, 2026 (senior author): LINC00511 drives osimertinib resistance in LUAD via PERK kinase: A clinical biomarker with enzymatic therapeutic potential. PubMed 42648586
- Front Oncol, 2026 (senior author): SUMOylation counteracts ubiquitination to stabilize ANKRD1 and promote osimertinib resistance in lung adenocarcinoma. PubMed 42991359
- Front Biosci (Landmark Ed), 2026 (senior author): CRABP2 Promotes Lung Adenocarcinoma Through Retinoic Acid Pathway-Mediated NF-κB Activation. PubMed 42530247
- Medicine (Baltimore), 2025 (senior author): Immune infiltration and drug treatment response of angiogenesis-related LncRNA in lung adenocarcinoma. PubMed 40629658
- PLoS One, 2024 (senior author): MiR-155 promotes compensatory lung growth by inhibiting JARID2 activation of CD34+ endothelial progenitor cells. PubMed 38394221
- Cell Oncol (Dordr), 2024 (senior author): tRNA-derived fragments: mechanism of gene regulation and clinical application in lung cancer. PubMed 37642916
- Bioengineered, 2022 (senior author): Downregulated miR-18a and miR-92a synergistically suppress non-small cell lung cancer via targeting Sprouty 4. PubMed 35484993
- Respir Res, 2021 (senior author): Relationship between long non-coding RNA PCAT-1 expression and gefitinib resistance in non-small-cell lung cancer cells. PubMed 33980216
See the full PubMed search. Automatic matching can miss papers or include a namesake at the same hospital.
This profile has not been reviewed by the doctor. How we build this directory.
Want a specialist to review your case?
Send your records. We find a specialist in this field who can review your case and write a treatment plan with a cost estimate.
Get a specialist opinion